CHINA PHARMA HOLDINGS, INC. Proceeds from Lines of Credit
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Proceeds from Lines of Credit of $700.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-14
- CHINA PHARMA HOLDINGS, INC. proceeds from lines of credit for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. proceeds from lines of credit for the quarter ending 2024-09-30 was $0.00.
- CHINA PHARMA HOLDINGS, INC. proceeds from lines of credit for the quarter ending 2023-12-31 was $1.03M.
- CHINA PHARMA HOLDINGS, INC. proceeds from lines of credit for the quarter ending 2023-09-30 was -$6.17K.
- CHINA PHARMA HOLDINGS, INC. proceeds from lines of credit for fiscal 2025 was $700.00K, a 42.06% increase from fiscal 2024.
- CHINA PHARMA HOLDINGS, INC. proceeds from lines of credit for fiscal 2024 was $492.76K, a 67.85% decline from fiscal 2023.
- CHINA PHARMA HOLDINGS, INC. proceeds from lines of credit for fiscal 2023 was $1.53M, a 171.28% increase from fiscal 2022.
- CHINA PHARMA HOLDINGS, INC. proceeds from lines of credit for fiscal 2022 was $564.97K, a 85.24% decline from fiscal 2021.
USD
| Period end | Proceeds from Lines of Credit | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $700.00K 10-K · filed 2026-04-01 | ||||
| 2025-06-30 | $696.00K 10-Q · filed 2026-08-14 | ||||
| 2025-06-25 | $700.00K 10-Q · filed 2026-08-14 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $0.00 derived: sum of 2 quarters · filed 2026-04-01 | $492.76K 10-K · filed 2026-04-01 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $492.76K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $492.76K 10-Q · filed 2025-08-14 | ||||
| 2023-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.03M derived: sum of 2 quarters · filed 2025-03-31 | $1.53M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$6.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $498.94K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $505.11K 10-Q · filed 2024-08-14 | ||||
| 2022-12-31 | $564.97K 10-K · filed 2024-04-01 | ||||
| 2021-12-31 | $11.79K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $3.06M derived: sum of 2 quarters · filed 2022-11-14 | $3.83M 10-K · filed 2022-03-30 | ||
| 2021-09-30 | $3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $3.82M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $772.58K 10-Q · filed 2022-08-11 | ||||
| 2020-12-31 | $160.98K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $936.25K derived: sum of 2 quarters · filed 2022-03-30 | $2.86M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | $775.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.70M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $1.92M 10-Q · filed 2021-08-13 |
CNY
| Period end | Proceeds from Lines of Credit | Proceeds from Lines of Credit as first filed |
|---|---|---|
| 2025-06-25 | 5.00M CNY 10-Q · filed 2026-08-14 | 0.00 CNY 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |